Efficacy and effects of Tofacitinib

Tofacitinib’s therapeutic effect stems from its ability to inhibit a specific enzyme called JAK, which plays a role in signaling pathways in the immune system. By blocking JAK, tofacitinib helps regulate immune responses and reduce inflammation associated with autoimmune diseases.

Tofacitinib has been approved for the treatment of moderate to severe rheumatoid arthritis (RA) in adults who have not responded to other disease-modifying antirheumatic drugs (DMARDs). It can help reduce joint pain, swelling and stiffness caused by RA and improve patients' physical function and quality of life. Tofacitinib has also shown efficacy in treating ankylosing spondylitis, another autoimmune disease characterized by skin symptoms such as arthritis and psoriasis, by relieving joint pain, reducing psoriatic skin lesions, and improving patients' physical function. Tofacitinib is approved for the treatment of moderately to severely active ulcerative colitis, and by inhibiting inflammatory signaling in the intestine, it can induce and sustain remission, reduce symptoms such as abdominal pain and diarrhea, and promote mucosal healing.

Tofacitinib has been launched in China and has entered the scope of Class B medical insurance. The common specification is tofacitinib citrate tablets. The price paid by medical insurance is relatively cheap, butthe reimbursement ratio is different in different regions, and the price after reimbursement will be different. Overseas, there are also generic drugs of tofacitinib produced in other countries. The price of each box produced by a Bangladeshi pharmaceutical factory is around 300 yuan (the price may fluctuate due to the exchange rate). The ingredients of domestic original drugs and foreign generic drugs are basically the same, and the prices of different specifications will be different.